General Biotechnology

Stem-Cell Cash on a Winding Road They may not be investing in the companies themselves, but venture capitalists haven’t completely […]

Financial Snapshot For June 2004 Lackluster Performance

ImClone Hammered as Sales Lag Estimates Scandal-plagued ImClone Systems may have fallen off the road to recovery. While the company’s

Wanted: Drugs to Fight Bioterror “Amid new warnings about a possible summer of terror, the U.S. government is preparing to

Eco-Terror Cited as Top Threat Law enforcement officials warn that biotechnology firms, particularly those that conduct research on animals, must

The Drug Research War “Mention the term ‘outsourcing,’ and drug development probably doesn’t leap to mind. But this market, which

Biotechs struggle as IPOs find cool reception “Five initial public offerings had trading debuts Thursday, bringing mixed results and a

The Health-Care Catastrophe That Won’t Happen Why biotech gains will rein in medical costs. The lesson of info tech

The Health-Care Catastrophe That Won’t Happen Why biotech gains will rein in medical costs. The lesson of info tech

Will U.S. try to circumvent drug firms patent? : The furor over Abbott Laboratories’ 400 percent price increase last December